News & Updates
Filter by Specialty:
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
12 Apr 2022
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
Both surgery and use of stereotactic body radiation therapy (SBRT) result in a decrease in the mean tumour size of early-stage nonsmall cell lung cancer (NSCLC), a recent study has shown.
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
12 Apr 2022
Which signs separate MIS-C from COVID-19, Kawasaki disease, toxic shock syndrome?
Children with multisystem inflammatory syndrome in children (MIS-C) show significantly higher prevalence of cardiac complications, elevated markers of inflammation and cardiac damage, thrombocytopenia, and lymphopenia than do those with COVID-19, Kawasaki disease (KD), and toxic shock syndrome (TSS), reports a study.
Which signs separate MIS-C from COVID-19, Kawasaki disease, toxic shock syndrome?
12 Apr 2022
Transcranial direct current stimulation enhances social functioning in autism spectrum disorder
A two-armed, double-blind, sham-controlled trial conducted by researchers at the Hong Kong Polytechnic University and the Chinese University of Hong Kong has demonstrated that transcranial direct current stimulation (tDCS) significantly enhances social functioning in individuals with autism spectrum disorder (ASD), when delivered concurrently with a computerized cognitive remediation training programme.
